Share DIPG/DMG tumor information for an international registry
Part of Brain & nervous system, Cancer clinical trials.
This trial builds an international registry (a secure collection of patient records) for people who have been diagnosed with DIPG/DMG, including children and adults. Sharing information can help researchers better understand these tumors and plan future studies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (or your child) have a known past or current diagnosis of DIPG or DMG
- If you are still alive, you and/or a parent or legal guardian must sign consent forms
- Consent includes permission to use your information for research (including HIPAA release)
- Deceased patients can be included based on their diagnosis, without needing active consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a targeted medicine approach for high-grade glioma (a fast-growing brain tumor) and some diffuse midline tumors, including DIPG. It may help by matching treatment to tumor biology using tumor testing done before or around starting standard therapy.
This early-phase trial tests a customized vaccine (made from your tumor’s cell parts) along with an immune “checkpoint blocker” medicine. It’s for newly diagnosed DIPG/DMG to see if this combination is safe and can help control the cancer.
This trial tests a combination of a vaccine made from tumor cells and a drug that may boost the immune system's ability to fight brain tumors. It is for children and young adults with a recurrent high-grade glioma or a newly diagnosed diffuse midline glioma with a specific genetic marker (H3K27M).
This Phase 2 trial studies whether a combination of medicines (including ONC201/related study drugs) can better treat diffuse midline gliomas, a type of brain/spinal cord tumor that often affects the midline. You may qualify if your tumor diagnosis is confirmed and your treatment timing (before radiation, after radiation, or at recurrence) matches one of the study groups.
This phase 3 study tests targeted treatments (ONC201 or everolimus) for children with DIPG or similar diffuse midline brain tumors, based on the tumor’s genetic markers. It aims to improve outcomes by matching treatment to the tumor biology and comparing approaches in a randomized way.
This is an observational study that collects and compares information from patients with primary brain tumors and their treatment results. It uses stored tumor tissue and brain scans to better understand outcomes using updated tumor classification methods.
Hear when a new Diffuse Intrinsic Pontine Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.